SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Won Young Tak, Jin Mo Yang, Byung Ik Kim, Soon Koo Baik, Gab Jin Cheon, Kwan Soo Byun, Do Young Kim, Byung Chul Yoo, A randomized, open-label study comparing low-dose clevudine plus adefovir combination therapy with clevudine monotherapy in naïve chronic hepatitis B patients, Hepatology International, 2014, 8, 3, 375

    CrossRef

  2. 2
    Deri Feng, Jiaan Liu, Shuang Liang, Yanyan Wang, Youjun Xu, Synthesis and biological evaluation of entecavir 4′-ester derivatives, Chemical Research in Chinese Universities, 2014, 30, 5, 749

    CrossRef

  3. 3
    Cungang Ding, Qinghua Ge, Yemu Wang, Zhen Zhou, Xiaojin Zhi, Xiaofen Liu, Zhou Li, Normal-phase liquid chromatography coupled with electrospray ionization mass spectrometry for chiral separation and quantification of clevudine and its enantiomer in human plasma, Journal of Chromatography B, 2012, 885-886, 97

    CrossRef

  4. 4
    Sang Myung Woo, Joong-Won Park, Woo Jin Lee, Chang-Min Kim, Clinical and Virological Responses to Clevudine Therapy of Hepatocelluar Carcinoma Patients with Chronic Hepatitis B, Gut and Liver, 2011, 5, 1, 82

    CrossRef

  5. 5
    Tomasz Cytlak, Henryk Koroniak, Photochemical transformations of 5-perfluoroalkenyl uracils, Journal of Fluorine Chemistry, 2011, 132, 10, 846

    CrossRef

  6. 6
    J. H. Kim, H. J. Yim, E. S. Jung, Y. K. Jung, J. H. Kim, Y. S. Seo, J. E. Yeon, H. S. Lee, S. H. Um, K. S. Byun, Virologic and biochemical responses to clevudine in patients with chronic HBV infection- associated cirrhosis: data at week 48, Journal of Viral Hepatitis, 2011, 18, 4
  7. 7
    Erik De Clercq, Geoffrey Férir, Suzanne Kaptein, Johan Neyts, Antiviral Treatment of Chronic Hepatitis B Virus (HBV) Infections, Viruses, 2010, 2, 6, 1279

    CrossRef

  8. 8
    Won Young Tak, Soo Young Park, Chang Min Cho, Min Kyu Jung, Seong Woo Jeon, Young Oh Kweon, Ji Young Park, Yoon Kyung Sohn, Clinical, biochemical, and pathological characteristics of clevudine-associated myopathy, Journal of Hepatology, 2010, 53, 2, 261

    CrossRef

  9. 9
    Hyeon Woong Yang, Byung Seok Lee, Tae Hee Lee, Heon Young Lee, Kwan Woo Nam, Young Woo Kang, Hee Bok Chae, Seok Hyun Kim, Seok Bae Kim, Hyang Ie Lee, An Na Kim, Il Han Song, Sae Hwan Lee, Hong Su Kim, Efficacy of Initial Treatment with Clevudine in Naive Patients with Chronic Hepatitis B, The Korean Journal of Internal Medicine, 2010, 25, 4, 372

    CrossRef

  10. 10
    In Hee Kim, Seok Lee, Seong Hun Kim, Sang Wook Kim, Seung Ok Lee, Soo Teik Lee, Dae Ghon Kim, Chang Soo Choi, Haak Cheoul Kim, Treatment Outcomes of Clevudine versus Lamivudine at Week 48 in Naïve Patients with HBeAg Positive Chronic Hepatitis B, Journal of Korean Medical Science, 2010, 25, 5, 738

    CrossRef

  11. 11
    Robert Perrillo, Sleisenger and Fordtran's Gastrointestinal and Liver Disease, 2010,

    CrossRef

  12. 12
    Emilio Palumbo, Clevudine for Chronic Hepatitis B, Infectious Diseases in Clinical Practice, 2009, 17, 4, 217

    CrossRef

  13. 13
    Byung Kook Kim, Jeeyoung Oh, So Young Kwon, Won Hyeok Choe, Soon Young Ko, Kyoung Hoon Rhee, Tae Ho Seo, So Dug Lim, Chang Hong Lee, Clevudine myopathy in patients with chronic hepatitis B, Journal of Hepatology, 2009, 51, 4, 829

    CrossRef

  14. 14
    Jean-Pierre Zarski, Les nouvelles molécules dans la prise en charge de l’hépatite chronique virale B, La Presse Médicale, 2009, 38, 5, 692

    CrossRef

  15. 15
    Heon Ju Lee, Jong Ryul Eun, Chang Hyeong Lee, Jae Seok Hwang, Jeong Ill Suh, Byung Seok Kim, Byoung Kuk Jang, Long-term clevudine therapy in nucleos(t)ide-naïve and lamivudine-experienced patients with hepatitis B virus-related chronic liver diseases, The Korean Journal of Hepatology, 2009, 15, 2, 179

    CrossRef

  16. 16
    Won Young Tak, Soo Young Park, Min Kyu Jung, Seong Woo Jeon, Chang Min Cho, Young Oh Kweon, Sung Kook Kim, Yong Hwan Choi, Mitochondrial myopathy caused by clevudine therapy in chronic hepatitis B patients, Hepatology Research, 2009, 39, 9
  17. 17
    Russell D. Fleischer, Anna S.F. Lok, Myopathy and neuropathy associated with nucleos(t)ide analog therapy for hepatitis B, Journal of Hepatology, 2009, 51, 4, 787

    CrossRef

  18. 18
    Jonathan K Watts, Masad J Damha, 2′F-Arabinonucleic acids (2′F-ANA) — History, properties, and new frontiers, Canadian Journal of Chemistry, 2008, 86, 7, 641

    CrossRef

  19. 19
    D Eldon Spackman, David L Veenstra, A Cost-Effectiveness Analysis of Currently Approved Treatments for HBeAg-Positive Chronic Hepatitis B, PharmacoEconomics, 2008, 26, 11, 937

    CrossRef

  20. 20
    Geoffrey Férir, Suzanne Kaptein, Johan Neyts, Erik De Clercq, Antiviral treatment of chronic hepatitis B virus infections: the past, the present and the future, Reviews in Medical Virology, 2008, 18, 1
  21. 21
    Tarik Asselah, Olivier Lada, Rami Moucari, Patrick Marcellin, Clevudine: a promising therapy for the treatment of chronic hepatitis B, Expert Opinion on Investigational Drugs, 2008, 17, 12, 1963

    CrossRef

  22. 22
    S. G. LIM, N. LEUNG, H. W. L. HANN, G. K. K. LAU, C. TREPO, H. MOMMEJA-MARIN, C. MOXHAM, J. SORBEL, A. SNOW, M. R. BLUM, F. ROUSSEAU, P. MARCELLIN, Clinical trial: a phase II, randomized study evaluating the safety, pharmacokinetics and anti-viral activity of clevudine for 12 weeks in patients with chronic hepatitis B, Alimentary Pharmacology & Therapeutics, 2008, 27, 12
  23. 23
    Fabien Zoulim, Données actuelles sur le traitement de l’hépatite B chronique, La Presse Médicale, 2008, 37, 2, 287

    CrossRef

  24. 24
    Laurence Lacey, Rong-Nan Chien, Wan-Long Chuang, Raoh-Fang Pwu, Economic evaluation of chronic hepatitis B treatments in Taiwan, Journal of Gastroenterology and Hepatology, 2008, 23, 4
  25. 25
    Peng Liu, Ashoke Sharon, Chung K. Chu, Fluorinated nucleosides: Synthesis and biological implication, Journal of Fluorine Chemistry, 2008, 129, 9, 743

    CrossRef

  26. 26
    Emilio Palumbo, New Drugs for Chronic Hepatitis B: A Review, American Journal of Therapeutics, 2008, 15, 2, 167

    CrossRef

  27. 27
    Kazuyoshi Ohkawa, Tetsuo Takehara, Michio Kato, Matsuo Deguchi, Masanori Kagita, Hayato Hikita, Akira Sasakawa, Keisuke Kohga, Akio Uemura, Ryotaro Sakamori, Shinjiro Yamaguchi, Takuya Miyagi, Hisashi Ishida, Tomohide Tatsumi, Norio Hayashi, Supportive Role Played by Precore and PreS2 Genomic Changes in the Establishment of Lamivudine-Resistant Hepatitis B Virus, The Journal of Infectious Diseases, 2008, 198, 8, 1150

    CrossRef

  28. 28
    Jae Hyeon Moon, Mong Cho, Ki Tae Yoon, Jung Ho Bae, Jeong Heo, Gwang Ha Kim, Dae Hwan Kang, Geun Am Song, The efficacy of adefovir dipivoxil monotherapy and the incidence of genotypic resistance to adefovir dipivoxil in patients with lamivudine-resistant chronic hepatitis B infection, The Korean Journal of Hepatology, 2008, 14, 4, 503

    CrossRef

  29. 29
    P. Marcellin, T. Asselah, O. Lada, Traitement « à la carte » de l’hépatite chronique B, Gastroentérologie Clinique et Biologique, 2008, 32, 1, S1

    CrossRef

  30. 30
    F. Bailly, F. Zoulim, Traitement de l’hépatite B. Conduite thérapeutique, Gastroentérologie Clinique et Biologique, 2008, 32, 5, S172

    CrossRef

  31. 31
    T. Asselah, O. Lada, N. Boyer, M. Martinot, P. Marcellin, Traitement de l’hépatite chronique B, Gastroentérologie Clinique et Biologique, 2008, 32, 8-9, 749

    CrossRef

  32. 32
    M. Bourlière, P. Castellani, Traitement de l’hépatite chronique B : nouvelles perspectives, Gastroentérologie Clinique et Biologique, 2008, 32, 1, S64

    CrossRef

  33. 33
    George Lau, Patrick Marcellin, Marion Peters, Chronic hepatitis B: a global health problem requiring coherent worldwide treatment strategies, Hepatology International, 2007, 1, 2, 316

    CrossRef

  34. 34
    Byung Chul Yoo, Ju Hyun Kim, Tae-Hun Kim, Kwang Cheol Koh, Soon-Ho Um, Young Soo Kim, Kwan Sik Lee, Byung Hoon Han, Chae Yoon Chon, Joon-Yeol Han, Soo Hyung Ryu, Haak Cheoul Kim, Kwan Soo Byun, Seong Gyu Hwang, Byung-Ik Kim, Mong Cho, Kwon Yoo, Heon-Ju Lee, Jae Seok Hwang, Yun Soo Kim, Young-Suk Lee, Sung-Kyu Choi, Youn-Jae Lee, Jin-Mo Yang, Joong-Won Park, Myung-Seok Lee, Dae-Ghon Kim, Young-Hwa Chung, Se-Hyun Cho, Jong-Young Choi, Young-Oh Kweon, Heon Young Lee, Sook-Hyang Jeong, Hee-Won Yoo, Hyo-Suk Lee, Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off-therapy viral suppression, Hepatology, 2007, 46, 4
  35. 35
    Kwan Sik Lee, Kwan Soo Byun, Young-Hwa Chung, Seung Woon Paik, Joon-Yeol Han, Kwon Yoo, Hee-Won Yoo, Byung Chul Yoo, Hyo-Suk Lee, Clevudine Therapy for 24 Weeks Further Reduced Serum Hepatitis B Virus DNA Levels and Increased ALT Normalization Rates without Emergence of Viral Breakthrough than 12 Weeks of Clevudine Therapy, Intervirology, 2007, 50, 4, 296

    CrossRef

  36. 36
    Margarita Pardo, Javier Bartolomé, Vicente Carreño, Current Therapy of Chronic Hepatitis B, Archives of Medical Research, 2007, 38, 6, 661

    CrossRef

  37. 37
    Fabien Zoulim, Emerging drugs for hepatitis B, Expert Opinion on Emerging Drugs, 2007, 12, 2, 199

    CrossRef

  38. 38
    Kwan Sik Lee, Dong Joon Kim, Management of Chronic Hepatitis B, The Korean Journal of Hepatology, 2007, 13, 4, 447

    CrossRef

  39. 39
    Anna Suk–Fong Lok, Navigating the Maze of Hepatitis B Treatments, Gastroenterology, 2007, 132, 4, 1586

    CrossRef

  40. 40
    Emmet B. Keeffe, Patrick Marcellin, New and Emerging Treatment of Chronic Hepatitis B, Clinical Gastroenterology and Hepatology, 2007, 5, 3, 285

    CrossRef

  41. 41
    Chee-Kin Hui, Nancy Leung, Tony W.H. Shek, Hung Yao, Wai-Ki Lee, Jak-Yiu Lai, Sik-To Lai, Wai-Man Wong, Lawrence SW. Lai, Ronnie T.P. Poon, Chung-Mau Lo, Sheung-Tat Fan, George K.K. Lau, Sustained disease remission after spontaneous HBeAg seroconversion is associated with reduction in fibrosis progression in chronic hepatitis B Chinese patients, Hepatology, 2007, 46, 3
  42. 42
    L. F. Lacey, E. Gane, The cost-effectiveness of long-term antiviral therapy in the management of HBeAg-positive and HBeAg-negative chronic hepatitis B in Singapore, Journal of Viral Hepatitis, 2007, 14, 11
  43. 43
    P. Farci, L. Chessa, C. Balestrieri, G. Serra, M. E. Lai, Treatment of chronic hepatitis D, Journal of Viral Hepatitis, 2007, 14,
  44. 44
    Byung Chul Yoo, Ju Hyun Kim, Young-Hwa Chung, Kwan Sik Lee, Seung Woon Paik, Soo Hyung Ryu, Byung Hoon Han, Joon-Yeol Han, Kwan Soo Byun, Mong Cho, Heon-Ju Lee, Tae-Hun Kim, Se-Hyun Cho, Joong-Won Park, Soon-Ho Um, Seong Gyu Hwang, Young Soo Kim, Youn-Jae Lee, Chae Yoon Chon, Byung-Ik Kim, Young-Suk Lee, Jin-Mo Yang, Haak Cheoul Kim, Jae Seok Hwang, Sung-Kyu Choi, Young-Oh Kweon, Sook-Hyang Jeong, Myung-Seok Lee, Jong-Young Choi, Dae-Ghon Kim, Yun Soo Kim, Heon Young Lee, Kwon Yoo, Hee-Won Yoo, Hyo-Suk Lee, Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B, Hepatology, 2007, 45, 5
  45. 45
    Hyo-Suk Lee, Young-Hwa Chung, KwanSik Lee, Kwan Soo Byun, Seung Woon Paik, Joon-Yeol Han, Kwon Yoo, Hee-Won Yoo, Jin Heon Lee, Byung Chul Yoo, A 12-week clevudine therapy showed potent and durable antiviral activity in HBeAg-positive chronic hepatitis B, Hepatology, 2006, 43, 5
  46. 46
    L Fouillard, L Serfaty, J Gozlan, Adefovir therapy for lamivudine escape and hepatitis B virus reactivation after reduced intensity conditioning allogeneic stem cell transplantation, Bone Marrow Transplantation, 2006, 37, 6, 625

    CrossRef

  47. 47
    Stephen Locarnini, William S. Mason, Cellular and virological mechanisms of HBV drug resistance, Journal of Hepatology, 2006, 44, 2, 422

    CrossRef

  48. 48
    Brent E Korba, Phillip A Furman, Michael J Otto, Clevudine: a potent inhibitor of hepatitis B virusin vitroandin vivo, Expert Review of Anti-infective Therapy, 2006, 4, 4, 549

    CrossRef

  49. 49
    Christophe Mathé, Gilles Gosselin, l-Nucleoside enantiomers as antivirals drugs: A mini-review, Antiviral Research, 2006, 71, 2-3, 276

    CrossRef

  50. 50
    G. C. Farrell, N. C. Teoh, Management of chronic hepatitis B virus infection: a new era of disease control, Internal Medicine Journal, 2006, 36, 2
  51. 51
    Francis Y. Yao, Newer antiviral agents and therapeutic approaches for chronic hepatitis b, Current Hepatitis Reports, 2006, 5, 1, 14

    CrossRef

  52. 52
    J. García-Samaniego, Nuevos fármacos para el tratamiento de la hepatitis crónica por virus B, Gastroenterología y Hepatología, 2006, 29, 54

    CrossRef

  53. 53
    James Fung, Ching-Lung Lai, Man-Fung Yuen, Overcoming the problem of chronic hepatitis B, Drug Discovery Today: Therapeutic Strategies, 2006, 3, 2, 197

    CrossRef

  54. 54
    Patrick Marcellin, Olivier Lada, Prise en charge de la résistance aux antiviraux dans le traitement de l’hépatite chronique B, Gastroentérologie Clinique et Biologique, 2006, 30, 10, 5

    CrossRef

  55. 55
    Y.-F. Liaw, C.-M. Lee, R.-N. Chien, C.-T. Yeh, Switching to adefovir monotherapy after emergence of lamivudine-resistant mutations in patients with liver cirrhosis, Journal of Viral Hepatitis, 2006, 13, 4
  56. 56
    Daniel Yerly, Loriana Di Giammarino, Florian Bihl, Andreas Cerny, Targets of emerging therapies for viral hepatitis B and C, Expert Opinion on Therapeutic Targets, 2006, 10, 6, 833

    CrossRef

  57. 57
    Ira M. Jacobson, Therapeutic Options for Chronic Hepatitis B: Considerations and Controversies, The American Journal of Gastroenterology, 2006, 101, S1, S13

    CrossRef

  58. 58
    T. Berg, Therapie der Hepatitis B, Der Gastroenterologe, 2006, 1, 2, 117

    CrossRef

  59. 59
    Smruti R Mohanty, Sonia S Kupfer, Vijay Khiani, Treatment of chronic hepatitis B, Nature Clinical Practice Gastroenterology & Hepatology, 2006, 3, 8, 446

    CrossRef

  60. 60
    Maureen M. Jonas, Treatment of Chronic Hepatitis B in Children, Journal of Pediatric Gastroenterology and Nutrition, 2006, 43, Supplement 1, S56

    CrossRef

  61. 61
    Patrizia Farci, Treatment of chronic hepatitis D: New advances, old challenges, Hepatology, 2006, 44, 3
  62. 62
    Antonio Craxì, Giorgio Antonucci, Calogero Cammà, Treatment options in HBV, Journal of Hepatology, 2006, 44, S77

    CrossRef

  63. 63
    Anastasia Rivkin, A review of entecavir in the treatment of chronic hepatitis B infection, Current Medical Research and Opinion, 2005, 21, 11, 1845

    CrossRef

  64. 64
    Alex Yui Hui, Joseph Jao-Yiu Sung, Advances in chronic viral hepatitis, Current Opinion in Infectious Diseases, 2005, 18, 5, 400

    CrossRef

  65. 65
    Alex Yui Hui, Joseph Jao-Yiu Sung, Advances in chronic viral hepatitis, Current Opinion in Internal Medicine, 2005, 4, 6, 548

    CrossRef

  66. 66
    Yun-Fan Liaw, Nancy Leung, Richard Guan, George K.K. Lau, Ismail Merican, Geoff McCaughan, Edward Gane, Jia-Horng Kao, Masao Omata, Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update, Liver International, 2005, 25, 3
  67. 67
    Harry L.A. Janssen, George K.K. Lau, Chronic hepatitis B: HBeAg seroconversion after pegylated interferon and nucleos(t)ide analogs, Hepatology, 2005, 42, 6
  68. 68
    Chee-Kin Hui, George KK Lau, Clevudine for the treatment of chronic hepatitis B virus infection, Expert Opinion on Investigational Drugs, 2005, 14, 10, 1277

    CrossRef

  69. 69
    Vincent Soriano, Marina Nuñez, Julie Sheldon, Belen Ramos, Javier Garcia-Samaniego, Luz Martín-Carbonero, Ivana Maida, Juan Gonzalez-Lahoz, Complications in treating chronic hepatitis B in patients with HIV, Expert Opinion on Pharmacotherapy, 2005, 6, 16, 2831

    CrossRef

  70. 70
    Hari S. Conjeevaram, Disease status and therapeutic end points in hepatitis B, Current Hepatitis Reports, 2005, 4, 1, 5

    CrossRef

  71. 71
    Maria Buti, Rafael Esteban, Drugs in Development for Hepatitis B, Drugs, 2005, 65, 11, 1451

    CrossRef

  72. 72
    Thomas Berg, New perspectives in the treatment of HBeAg-positive and HBeAg-negative chronic hepatitis B, Hepatology, 2005, 41, 6
  73. 73
    Zhi Chen, Min Zheng, Patents and development of HBV and HCV clinical treatment: from 2001 to April 2005, Expert Opinion on Therapeutic Patents, 2005, 15, 8, 1027

    CrossRef

  74. 74
    W Graham E Cooksley, Peginterferon-α2afor the treatment of hepatitis B infection, Expert Opinion on Pharmacotherapy, 2005, 6, 8, 1373

    CrossRef

  75. 75
    Chee-kin Hui, George KK Lau, Peginterferon–α2a (40 kDa) (Pegasys®) for hepatitis B, Expert Review of Anti-infective Therapy, 2005, 3, 4, 495

    CrossRef

  76. 76
    Thomas Berg, Reply:, Hepatology, 2005, 42, 6
  77. 77
    David Durantel, Marie-Noelle Brunelle, Edwige Gros, Sandra Carrouée-Durantel, Christian Pichoud, Stephanie Villet, Christian Trepo, Fabien Zoulim, Resistance of human hepatitis B virus to reverse transcriptase inhibitors: from genotypic to phenotypic testing, Journal of Clinical Virology, 2005, 34, S34

    CrossRef

  78. 78
    Marie-Noëlle Brunelle, Anne-Carole Jacquard, Christian Pichoud, David Durantel, Sandra Carrouée-Durantel, Jean-Pierre Villeneuve, Christian Trépo, Fabien Zoulim, Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir, Hepatology, 2005, 41, 6
  79. 79
    Sreekala Satheesh, Robert P. Perrillo, Treatment of antiviral therapy for chronic hepatitis B: A disease in evolution, Current Hepatitis Reports, 2005, 4, 1, 14

    CrossRef

  80. 80
    P. Marcellin, T. Asselah, N. Boyer, Treatment of chronic hepatitis B, Journal of Viral Hepatitis, 2005, 12, 4
  81. 81
    Scott K Fung, Anna S. F Lok, Update on viral hepatitis in 2004, Current Opinion in Internal Medicine, 2005, 4, 4, 359

    CrossRef

  82. 82
    Scott K Fung, Anna SF Lok, Drug Insight: nucleoside and nucleotide analog inhibitors for hepatitis B, Nature Clinical Practice Gastroenterology & Hepatology, 2004, 1, 2, 90

    CrossRef

  83. 83
    Stephanos J Hadziyannis, George V Papatheodoridis, Emerging treatments in chronic hepatitis B, Expert Opinion on Emerging Drugs, 2004, 9, 2, 207

    CrossRef

  84. 84
    Tarik Asselah, Corinne Castelnau, Nathalie Boyer, Marie-Pierre Ripault, Patrick Marcellin, Traitement de l’hépatite chronique B, Gastroentérologie Clinique et Biologique, 2004, 28, 12, 1215

    CrossRef

  85. 85
    Rebecca Saich, Roger Chapman, What's new in … Liver disorders: part 2, Medicine, 2002, 30, 11, 1

    CrossRef

  86. 86
    Anita Arora, Natalia Mendoza, Stephen K. Tyring, Antiviral Market Overview, Pharmaceutical Sciences Encyclopedia,
  87. 87
    Ashoke Sharon, Ashok K. Jha, Chung K. Chu, Clevudine, to Treat Hepatitis B Viral Infection,
  88. 88
    Xiao-Long Qiu, Xuyi Yue, Feng-Ling Qing, Fluorine-Containing Chiral Drugs,